Novocure Reports Third Quarter 2015 Operating and Financial Results
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, today reported operating and financial results for the three and nine months ended September 30, 2015. “The last few months were marked by a number of significant milestones. Most notably, on October 5, we received FDA approval …